Kim A Reiss

7PUBLICATIONS
53CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

|Jul 09, 2025
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes.

Sriram Anbil, Nicholas J Seewald, E Gabriela Chiorean

|Aug 09, 2024
KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.

Minh T Than, Mark O'Hara, Ben Z Stanger

|Jul 24, 2023
The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.

Timothy J Brown, Arielle Yablonovitch, Jacob E Till

|May 16, 2023
Advancements in Systemic Therapy for Pancreatic Cancer.

Timothy J Brown, Kim A Reiss, Mark H O'Hara

|May 10, 2021
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.

Kim A Reiss, Rosemarie Mick, Mark H O'Hara

Pageof 2

Frequent Collaborators

4 joint publications

Katherine Nathanson

3 joint publications

Mark O'Hara

3 joint publications

Susan M Domchek

2 joint publications

Thomas B Karasic